Use of high dose factor VIIa in hemophilia patients.
作者信息
Hedner U
机构信息
Novo Nordisk, A/S, Målov, Denmark.
出版信息
Adv Exp Med Biol. 2001;489:75-88. doi: 10.1007/978-1-4615-1277-6_7.
PMID:11554593
Abstract
摘要
相似文献
1
Use of high dose factor VIIa in hemophilia patients.
Adv Exp Med Biol. 2001;489:75-88. doi: 10.1007/978-1-4615-1277-6_7.
2
Current concepts in diagnosis and management of hemophilia.
Hosp Pract (Off Ed). 1982 Oct;17(10):77-84, 89-92. doi: 10.1080/21548331.1982.11702390.
3
Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
Br J Haematol. 2013 Jan;160(2):153-70. doi: 10.1111/bjh.12091. Epub 2012 Nov 15.
4
Key issues in inhibitor management in patients with haemophilia.
Blood Transfus. 2014 Jan;12 Suppl 1(Suppl 1):s319-29. doi: 10.2450/2013.0246-12. Epub 2013 Dec 3.
5
Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
Thromb Haemost. 1998 Dec;80(6):912-8.
6
Continuous infusion of recombinant factor VIIa: continue or not?
Thromb Haemost. 2001 Oct;86(4):942-4.
7
Pioneering therapeutic proteins in hemophilia care through innovative technologies.
Thromb Res. 2016 May;141 Suppl 3:S1. doi: 10.1016/S0049-3848(16)30413-3.
8
Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery.
Thromb Haemost. 1998 Nov;80(5):773-8.
9
Advances in the care and treatment of children with hemophilia.
Adv Pediatr. 2010;57(1):287-94. doi: 10.1016/j.yapd.2010.08.007.
10
Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
Thromb Haemost. 1999 Aug;82(2):531-9.
Zotero 插件